Hideki Hirakata
Fukuoka Dental College
Internal medicineUrologyEndocrinologySurgeryPathologyRenal functionCardiologyIntensive care medicineImmunologyHazard ratioHemodialysisAnemiaKidney diseaseDialysisKidneyCreatinineNephropathyNephrologyMedicineGastroenterology
264Publications
57H-index
7,458Citations
Publications 267
Newest
#1Kazuhiko Tsuruya (Nara Medical University)H-Index: 37
#2Hisatomi Arima (Fukuoka University)H-Index: 23
Last. Hideki HirakataH-Index: 57
view all 0 authors...
Background null Dialysis-related amyloidosis (DRA) commonly develops in patients undergoing long-term dialysis and can lead to a decline in activities of daily living and quality of life (QOL), mainly owing to orthopedic complications. null Methods null First, we determined utility scores of the EuroQol 5-Dimensions 3-Levels (EQ-5D-3L) questionnaire in 1,323 patients with DRA who had undergone dialysis for more than 10 years and compared the score between those with and without DRA. Second, a 2-...
Source
#1Tadao Akizawa (Showa University)H-Index: 62
#2Masaomi Nangaku (UTokyo: University of Tokyo)H-Index: 80
Last. Hideki HirakataH-Index: 57
view all 7 authors...
Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed for treating anemia in chronic kidney disease. Two open-label, uncontrolled phase 3 studies evaluated the 52-week safety and efficacy of enarodustat in Japanese anemic patients with chronic kidney disease not on dialysis (n = 132) [SYMPHONY ND-Long study] or on maintenance hemodialysis (n = 136) [SYMPHONY HD-Long study]. The most frequent adverse events were viral upper respiratory tract infection (2...
1 CitationsSource
#1Yusuke KurokiH-Index: 3
#2Kei HoriH-Index: 11
Last. Takanari Kitazono (Kyushu University)H-Index: 64
view all 8 authors...
Background Lower blood pressure (BP) levels are linked to a slower decline of kidney function in patients with chronic kidney disease (CKD) without kidney replacement therapy. However, there are limited data on this relation in peritoneal dialysis (PD) patients. Here we evaluated the association of BP levels with the decline of residual kidney function (RKF) in a retrospective cohort study. null null Methods We enrolled 228 patients whose PD was initiated between 1998 and 2014. RKF was measured ...
Source
#1Hiroaki Ogata (Showa University)H-Index: 18
#2Masafumi Fukagawa (Tokai University)H-Index: 69
view all 8 authors...
Importance Among patients with hyperphosphatemia undergoing dialysis, it is unclear whether non-calcium-based phosphate binders are more effective than calcium-based binders for reducing cardiovascular events. Objective To determine whether lanthanum carbonate reduces cardiovascular events compared with calcium carbonate in patients with hyperphosphatemia at risk of vascular calcification undergoing hemodialysis. Design, setting, and participants Open-label, randomized, parallel-group clinical t...
1 CitationsSource
#1Tadao Akizawa (Showa University)H-Index: 62
#2Masaomi Nangaku (UTokyo: University of Tokyo)H-Index: 80
Last. Hideki HirakataH-Index: 57
view all 7 authors...
Abstract Introduction Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that might be a new therapeutic approach for managing anemia in patients with chronic kidney disease (CKD). We evaluated the efficacy (non-inferiority to darbepoetin alfa [DA]) and safety of enarodustat in Japanese anemic patients with CKD not requiring dialysis. Methods Erythropoiesis-stimulating agent (ESA)-naive patients and ESA-treated patients were randomized at a 1:1 ratio to receiv...
3 CitationsSource
#1Terumasa HayashiH-Index: 17
#2Hideki Kato (UTokyo: University of Tokyo)H-Index: 24
Last. Ichiei Narita (Niigata University)H-Index: 55
view all 20 authors...
Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is associated with cardiovascular events and poor renal outcome in patients with chronic kidney disease (CKD). This study aimed to investigate the initial responsiveness to darbepoetin alfa (DA) and its contributing factors using the data from the BRIGHTEN. Of 1980 patients enrolled at 168 facilities, 1695 were included in this analysis [285 patients were excluded mainly due to lack of hemoglobin (Hb) values]. The initial ESA respons...
1 CitationsSource
#1Eiichiro Kanda (Kawasaki Medical School)H-Index: 16
Last. Bruce M. RobinsonH-Index: 38
view all 10 authors...
The identification of malnutrition-inflammation-complex (MIC) and functional status (FS) is key to improving patient experience on hemodialysis (HD). We investigate the association of MIC and FS combinations with mortality in HD patients. We analyzed data from 5630 HD patients from 9 countries in DOPPS phases 4-5 (2009-2015) with a median follow-up of 23 [IQR 11, 31] months. MIC was defined as serum albumin 3 mg/L in Japan and > 10 mg/L elsewhere. FS score was defined as the sum of scores from t...
1 CitationsSource
Background There is no evidence regarding appropriate target hemoglobin levels in chronic kidney disease (CKD) patients with an erythropoiesis-stimulating agent (ESA)-hyporesponsiveness. Therefore, we conducted a randomized controlled study in non-dialysis dependent CKD (NDD-CKD) patients with ESA-hyporesponsiveness, comparing results of intensive versus conservative treatment to maintain hemoglobin levels. Methods This was a multicenter, open-label, randomized, parallel-group study conducted at...
Source
#1Shunsuke Yamada (Kyushu University)H-Index: 13
#2Toshiaki Nakano (Kyushu University)H-Index: 19
Last. Takanari Kitazono (Kyushu University)H-Index: 64
view all 11 authors...
Protein-energy wasting (PEW) is a frequently observed complication that leads to increased mortality in hemodialysis patients. However, a multifaceted assessment of PEW by combined objective nutritional parameters has not yet been established. In total, 144 Japanese patients receiving maintenance hemodialysis at a hemodialysis center were retrospectively followed for 7 years. The primary outcome was all-cause death. The main exposure was a modified simple PEW score (0, 1, 2, 3, or 4), calculated...
Source
#1Yusuke KurokiH-Index: 3
#2Koji MitsuikiH-Index: 9
Last. Toshiaki Nakano (Kyushu University)H-Index: 19
view all 7 authors...
BACKGROUND Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease that leads to end-stage kidney disease if only a poor response to plasma exchanges (PEs) or eculizumab therapy is achieved. CASE PRESENTATION A 58-year-old Japanese man presented with thrombocytopenia, anemia, and kidney failure requiring dialysis without any underlying disease. A kidney biopsy revealed marked mesangiolysis in all glomeruli, compatible with thrombotic microangiopathy (TMA). Based on the positive a...
Source